Juan F Rodríguez Moreno

Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?

J. García-Saenz, E. Díaz-Rubio, T. Alonso Gordoa, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment

J. García-Donas, L. Minig, I. Díaz-Padilla, 2013, Ecancermedicalscience.

Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients

Juan F Rodríguez Moreno, Elena Sevillano Fernández, Rodrigo Madurga de Lacalle, 2022, Journal of clinical medicine.

Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.

C. Rodríguez-Antona, I. Durán, E. Grande, 2022, Pharmacogenomics.

COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study

S. Puig, R. Rosell, M. Provencio, 2021, Journal of the American Academy of Dermatology.

Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D‐NRG1 gene fusion in prostate cancer by data‐drilling a de‐identified tumor database

R. Alaghehbandan, O. Hes, P. A. Navarro, 2021, Genes, chromosomes & cancer.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial

L. Cámpora, K. Jung, B. Rubio-Viqueira, 2019, Cancer.

458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)

S. Gettinger, L. Paz-Ares, V. Gontcharova, 2021, Journal for ImmunoTherapy of Cancer.

Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB.

J. García-Donas, L. Minig, N. Romero, 2014, World journal of clinical oncology.

Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study

E. Espinosa, L. Fernández-Morales, Á. Rodríguez-Lescure, 2023, Melanoma research.